DrugJan 3, 2024
Sertraline Tablets, USP 100 mg, 30 tablets per bottle recall — FDA D-0205-2024
CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
Class IIFDA: OngoingLegacy Pharmaceutical Packaging LLC
Recall history in this database
Classification mix: Class II: 8, Class III: 1.
DrugOct 7, 2020
Legacy Pharmaceutical Packaging Metformin Hydrochloride Tablets USP, 1000 mg, 60-count recall — FDA D-1626-2020
Presence of Foreign Tablets/Capsules: Metformin 1000mg with different imprint was found in bottles.
Class IIIFDA: TerminatedLegacy Pharmaceutical Packaging LLC
DrugMay 8, 2019
Legacy Pharmaceutical Packaging Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles recall — FDA D-1263-2019
CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)
Class IIFDA: OngoingLegacy Pharmaceutical Packaging LLC
DrugApr 10, 2019
Legacy Pharmaceutical Packaging Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles recall — FDA D-1075-2019
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.
Class IIFDA: TerminatedLegacy Pharmaceutical Packaging LLC
DrugMar 27, 2019
Legacy Pharmaceutical Packaging Losartan Potassium Tablets, USP, 100 mg, 30 tablet bottles recall — FDA D-1050-2019
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Class IIFDA: OngoingLegacy Pharmaceutical Packaging LLC
DrugMar 27, 2019
Legacy Pharmaceutical Packaging Losartan Potassium Tablets, USP, 25 mg, 30 tablet bottles recall — FDA D-1048-2019
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Class IIFDA: OngoingLegacy Pharmaceutical Packaging LLC
DrugMar 27, 2019
Legacy Pharmaceutical Packaging Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles recall — FDA D-1049-2019
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Class IIFDA: OngoingLegacy Pharmaceutical Packaging LLC
DrugMar 29, 2017
Legacy Pharmaceutical Packaging ATENOLOL Tablets, USP, 50 mg, 30-count bottle recall — FDA D-0606-2017
Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.
Class IIFDA: TerminatedLegacy Pharmaceutical Packaging LLC
DrugMay 22, 2013
Legacy Pharmaceutical Packaging Walmart Amlodipine Besylate Tablets, USP 10 mg recall — FDA D-319-2013
Labeling: Label Error on Declared Strength-The recalled product has a misprint on the Amoldipine 10 mg label, 5 mg is listed in the USP description. Tablet strength is 10 mg.
Class IIFDA: TerminatedLegacy Pharmaceutical Packaging LLC
Understanding this recall history
This page summarizes recall records in which the official source identifies Legacy Pharmaceutical Packaging LLC as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.